Key Drivers
- Strong profitability
- Excellent liquidity
- Rich valuation
AIAI Summary
KRYS should now be viewed less as a financing-risk biotech and more as a high-quality commercial platform with durable VYJUVEK cash flows, but at ~41x earnings the stock's main risk is no longer survival—it's whether international expansion and pipeline catalysts can keep growth ahead of premium expectations and recent momentum weakness.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong profitability
- •Excellent liquidity
- •Rich valuation
KRYS remains highly profitable and cash-generative with exceptional liquidity and minimal debt, but the stock appears richly valued and recent cash decline reflects heavy investment outflows.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support holding
- •Weak momentum
KRYS remains in a weak downtrend over the last month, but support in the $312–$325 zone is helping stabilize the pullback while a move above $340–$367 is needed to improve the setup.
Sharp selloff after the 2026-07-30 peak, followed by a partial rebound from the 2026-08-03 low
Sentiment & News
Key News Insights:
- •Vyjuvek momentum
- •Strong balance sheet
- •Pipeline catalysts
Krystal Biotech's recent headlines highlight strong Vyjuvek-driven revenue growth, solid profitability and cash generation, and an expanding late-stage pipeline, though the stock reaction to the earnings beat was muted.
These updates suggest improving fundamental performance and multiple upcoming catalysts, supporting a constructive long-term outlook despite near-term share-price volatility
Similar Companies in Healthcare
Other companies in the same sector with AI ratings